Purchase Order HHSN272201701145P

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Adaptive Biotechnologies Corporation for $20,000 on July 11, 2019, with an ultimate completion date of July 11, 2020. Work is performed at Bethesda, Maryland. The order procures immunosequencing services under firm fixed-price commercial terms. No set-aside was used.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Adaptive Biotechnologies Corporation for immunosequencing services (ImmunoSEQ MMTCRB sequencing) valued at $12,200.00, with award and completion dates of July 12, 2018 and July 12, 2019 respectively.</p> <p>Performance occurs in Seattle, Washington. The order is firm fixed price with no set-aside designation.</p>

The National Institute of Allergy and Infectious Diseases awarded a purchase order to Adaptive Biotechnologies Corporation for $11,475 on November 2, 2020, for immunosequencing extraction services. Work is performed in Seattle, Washington. The order carries a firm fixed-price structure with an ultimate completion date of December 31, 2020. This award was issued to administratively de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in...

<p>The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $308,400 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, to provide COVID-19 funded immunoseq sequencing services for a COVID-19 research project. The contract will be performed in Seattle, Washington and has a period of performance from November 10, 2022 through May 10, 2023.</p>

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a purchase order to Adaptive Biotechnologies Corporation for DNA extraction services (ImmunoSEQ) valued at $21,225.00 on September 15, 2021. Performance is located in Bethesda, Maryland. The order is priced on a firm fixed-price basis with no small business set-aside. The ultimate completion date is January 7, 2022. This purchase order supports the FY26 UDO Initiative DNA Extraction Services requirement and procures...

Adaptive Biotechnologies Corporation has been awarded a firm fixed price purchase order valued at thirteen thousand two hundred dollars from the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, Adaptive will provide laboratory testing, adaptive immunosequencing, and DNA extraction services in support of unspecified NIH research programs. Performance will take place in Seattle, Washington through...

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $14,690 firm fixed-price purchase order to Adaptive Biotechnologies Corporation (doing business as Adaptive) for ImmunoSEQ sequencing services. The contract has an ultimate completion date of December 20, 2024. Adaptive is a commercial provider of immune-driven medicine services and products, and has previously received federal contracts and grants from the Department of Health and Human Services (HHS), Department...

The Department of Health and Human Services (HHS) National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $61,150.00 firm fixed price purchase order to Adaptive Biotechnologies Corporation, doing business as Adaptive, for SARS-COV-2 immunosequencing testing services. The contract has a performance period through September 30, 2024 and was awarded on May 7, 2024. Adaptive has previously provided specialized testing and genomic sequencing services to HHS,...

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), awarded a $22,280.00 firm fixed price purchase order contract to Adaptive Biotechnologies Corporation (Adaptive) for immunosequencing services. The 1-year contract with a completion date of September 22, 2025 does not have a set-aside designation. Adaptive provides immune-driven medicine products and services, and has previously been awarded...

Adaptive Biotechnologies Corporation, doing business as Adaptive, has been awarded a firm fixed price purchase order valued at thirteen thousand four hundred dollars from the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, Adaptive will provide immunosequencing and laboratory testing services in support of the agency's research programs. Specifically, Adaptive will deliver T-cell receptor beta...